BSECompany Update1d ago · 24 Sept 2026, 03:25 pm

Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is attached herewith

Gufic Biosciences Ltd · 509079

✦ AI Summary▼ NegativeRegulatory

Gufic Biosciences Ltd has received a letter from NSE rejecting its waiver application for a penalty of ₹1,72,000 for non-compliance with SEBI regulations regarding the appointment of an independent director without shareholder approval.

Analysis Scores

Earnings Impact0/10
Growth Catalyst0/10
Governance Concern2/10
Regulatory Risk8/10
Balance Sheet Risk0/10
Liquidity Impact0/10
Market Sentiment2/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Gufic Biosciences Ltd - 509079 - Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

Attachments (1)

📄

997cdf35-67cd-40b2-9d97-0ece0a3df9eb.pdf

pdf

Download →
View document text
284/LG/SE/SEP/2026/GBSL September 24, 2026 To To BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra Kurla Complex, Dalal Street, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code : 509079 Scrip Symbol : GUFICBIO Subject: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Dear Sir/Madam, This is in continuation to the Company’s earlier intimation dated August 22, 2024 vide Ref. No. 202/LG/SE/AUG/2024/GBSL and November 22, 2024 vide Ref. No. 282/LG/SE/NOV/2024/GBSL informing about the penalties of ₹8000/- (excluding GST) and ₹1,72,000/- (excluding GST) each levied by BSE Limited (“BSE”) and National Stock Exchange of India Limited (“NSE”) for the quarters ended June 2024 and September 2024 respectively, in relation to the alleged non-compliance with the provisions of Regulation 17(1A) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, pertaining to the appointment of Mr. Kamal Kishore Seth (DIN: 00194986) as an Additional Director (Non-Executive Independent Director) of the Company, who had attained the age of seventy-five years, without obtaining shareholders’ approval by way of a special resolution. The Company had filed Waiver Applications with BSE and NSE seeking waiver of the aforesaid penalties imposed. In the interim, the Company had paid the penalty of ₹8000/- (excluding GST) each to BSE and NSE for the quarter ended June 30, 2024. Subsequently, BSE had rejected the above waiver application, which was duly intimated to the Stock Exchanges on March 13, 2026. The Company has now received a letter dated September 23, 2026, from NSE rejecting the above waiver application filed by the Company. Accordingly, the penalty of ₹1,72,000/- (excluding GST) levied by NSE for the quarter ended September 30, 2024 is required to be paid on or before October 03, 2026. The Company shall accordingly make the payment within the timeline stipulated by NSE. Kindly take the same on your record. Thanking You, Yours truly, For Gufic Biosciences Limited Ami Shah Company Secretary & Compliance Officer Membership No. A39579